Fig. 4: YAP1 triggers the migration/invasion ability of EMT and CCA cells.

A Migratory abilities of HuCCT1 and SNU-1079 cells treated with regorafenib (0.01, 0.1, 1, and 10 μM), evaluated by Giemsa staining. B Quantitation of migration ability of HuCCT1 and SNU-1079 cells treated with regorafenib (0.01, 0.1, 1, and 10 μM). C Western blots showing E-cadherin, vimentin, and SNAI2 protein levels after treatment of HuCCT1 cells with YAP1 inhibitors verteporfin (10 μM) and regorafenib (10 μM), respectively. D Western blots showing E-cadherin, vimentin, and SNAI2 protein levels after treatment of SNU-1079 cells with YAP1 inhibitors verteporfin (10 μM) and regorafenib (10 μM), respectively. E Western blots show E-cadherin, vimentin, and SNAI2 protein levels after treating HuCCT1 cells with YAP1 shRNAs, respectively. F Quantitation of migration/invasion ability of HuCCT1 cells treated with or without verteporfin (1 μM and 10 μM), regorafenib (10 μM) and YAP1 shRNAs, respectively. G Western blots showing phospho-YAP1, YAP1, E-cadherin, vimentin, and SNAI2 protein levels after treatment of HuCCT1 cells with regorafenib (10 μM) or combined with YAP1 overexpression plasmids, respectively. H Quantitation of migration/invasion ability of HuCCT1 cells treated with regorafenib (10 μM) with or without YAP1 overexpression plasmids, respectively. Data are presented as the mean of three independent experiments ± SEM. The significance of the difference was determined using a nonparametric Mann–Whitney U-test.